Professional Documents
Culture Documents
Participants Guide
Selection
Use
Management
Support
Distribution
M14
Procurement
This publication was made possible through support provided by the US Agency for International
Development, under the terms of cooperative agreement number HRN-A-00-92-00059-13. The opinions
expressed herein are those of the author(s) and do not necessarily reflect the views of the US Agency for
International Development.
This session is derived from Chapter 40, Drug Financing Strategies, Chapter 42, Financial
Planning and Management, and Chapter 44, Revolving Drug Funds, in Managing Drug Supply:
The Selection, Procurement and Use of Pharmaceuticals, 2d ed., revised and expanded, by Management Sciences for Health with the World Health Organization (West Hartford, CT: Kumarian Press,
Inc., 1997). Used with permission. ISBN 1-56549-047-9
To order Managing Drug Supply, contact:
Kumarian Press, Inc.
14 Oakwood Avenue
West Hartford, CT 06119-2127
US
M14
This training module is based on materials from Managing Drug Supply, second edition. The
chapters pertaining to this module are highlighted below.
Part I
Part II
Introduction Policy and
Legal
Framework
Part III
Drug
Management
Cycle
Part IV
Management Support
Systems
Section A
Organization and
Management
Section B
Financing and
Sustainability
Section C
Information
Management
Section D
Human Resources
Management
Objectives
After completing this session, you will be able to:
Identify current options for financing essential drugs supply and evaluate the
appropriateness of each option.
Review financing mechanisms used in other countries and assess the financing
options for your own country and health system.
Preparation
Read:
Further Reading
Topics
Introduction
Summary of Session
Activity One
Sources of Drug Funding
Rationale
There are various sources for funding drug supply. You will be asked to identify the sources you
rely on in your program. This will help you better understand the kinds of programs represented
in the course and identify those with similar strengths and weaknesses in funding.
Instructions
1.
Fill in the headings of Worksheet 1: Sources of Drug Funding with the breakdown of
funding sources for your program. If you do not know the exact breakdown, you may
estimate.
2.
As other participants present their situations, make notes on your worksheet. Be prepared to
discuss your observations.
3.
Participants
Countries
Worksheet 1
Sources of Drug Funding
Total
100%
100%
100%
100%
100%
100%
100%
100%
Put an approximate percentage in each box so that each row sums to 100 percent.
Activity Two
Current Health and Drug Expenditures
Rationale
This activity aims to stimulate your thinking about the current health and drug financing situation
in your program.
Instructions
1.
2.
For each statement on Worksheet 2: Current Health and Drug Expenditures, reach a
consensus on whether the statement is true or false in the context of your countries. If a
statement is false, reword it to make it true.
Worksheet 2
Current Health and Drug Expenditures
Reach consensus on whether these statements are true or false in the context of your countries. If
a statement is false, reword it to make it true.
True
False Dont
Know
9. NGOs play a bigger role than the government in the financing and
provision of health services.
10. Per capita drug consumption varies greatly within the region.
Activity Three
Financing Options for Essential Drugs
Rationale
This activity should help you develop a financial strategy for making the best use of each funding
source. A drug financing strategy must consider all the efforts a country is making to improve the
use of available funds and the selection, procurement, distribution, and use of drugs. The strategy
should also advocate increased funding (from government, user fees, health insurance, and donor
assistance). It will also allow you to think about quality of care in concrete terms by identifying
important evaluation criteria.
Instructions
1.
2.
Worksheet 3
Illustrative Comparison of Funding Mechanisms
89 f
Availability of
Essential Drugs
(Access)
8a
9m
89 g
89 g
8b
8h
:c
89 s
8j
8i
89 d
8t
8q
8n
89 e
Sustainability
89
8 needed r
:sector
8k
Administrative
Requirements
Evaluation Criteria
8l
89 p
89
Funding Mechanism
Community drug
schemes
Direct private drug
purchases
Health Insurance
8o
89
needed
Donor Financing
Equity
Social
8o
Efficiency
Private
8o
89
Appropriate Drug
Use
Managed care
89
89
Public Financing
through Government
Budgets
User Fees
Community Financing
89
Government revolving
drug funds (RDF)
Bilateral
Development loans
Key to Worksheet 3
Illustrative Comparison of Funding Mechanisms
Key:
8
9
89
:
increases
decreases
may increase or decrease
uncertain
no change
Notes:
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
l.
m.
n.
o.
p.
q.
r.
s.
t.
10
Slide 1
________________________________
________________________________
Managing Drug Supply
Financing Drug Supply
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
________________________________
Slide 2
Unit Objectives
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 1
________________________________
_____________________
Slide 3
________________________________
Unit Outline
A.
Introduction
B.
C.
D.
E.
F.
G.
FIN 2
Summary of Session
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
11
Slide 4
________________________________
The Financial Sustainability Equation
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 3A
________________________________
_____________________
Slide 5
________________________________
Financial Sustainability Equation
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
________________________________
Slide 6
Components of the FSE
Demand:
availability
affordability
perceived quality
alternative choices
administrative controls
FIN 4A
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
12
Slide 7
________________________________
Components of the FSE, cont.
Financial Resources:
________________________________
________________________________
government financing
user fees
________________________________
social insurance
community financing
________________________________
donor financing
________________________________
FIN 4B
________________________________
_____________________
________________________________
Slide 8
Components of the FSE, cont.
Costs:
administration
purchases
personnel
operating costs
Quality of Care:
availability of drugs
selection of drugs
quality of drugs
capital
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 4C
________________________________
_____________________
Slide 9
________________________________
Options for Decision Makers
Improve efficiency
Increase financial resources
________________________________
________________________________
Reduce demand
________________________________
________________________________
FIN 5
________________________________
________________________________
_____________________
13
Slide 10
________________________________
Examples of Supply System Efficiencies
________________________________
Selection:
fewer drugs
cost-effective choices of drugs
________________________________
________________________________
Procurement:
accurate quantification
wise buying
good prices
reduction in losses from unreliable suppliers
________________________________
________________________________
FIN 6A
________________________________
_____________________
Slide 11
________________________________
________________________________
________________________________
________________________________
________________________________
Use:
standard treatments
prescription controls
________________________________
FIN 6B
________________________________
_____________________
________________________________
Slide 12
Funding Options for Essential Drugs
Public financing
(government budgets):
national government
local government
FIN 7A
________________________________
User fees:
public-sector revolving
drug funds
community drug
schemes
direct private drug
purchases (out-ofpocket purchases)
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
14
Slide 13
________________________________
Funding Options for Essential Drugs, cont.
Health insurance (prepaid health schemes):
social insurance
private insurance
managed care
community health insurance
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 7B
________________________________
_____________________
________________________________
Slide 14
Funding Options for Essential Drugs, cont.
Voluntary and other local financing:
private voluntary (PVOs)
voluntary community mechanisms
cooperatives
employer-provided health care
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 7C
________________________________
_____________________
Slide 15
________________________________
Funding Options for Essential Drugs, cont.
Donor financing:
bilateral grants
multilateral grants
Development loans:
World Bank
regional development banks
FIN 7D
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
15
Slide 16
________________________________
Determinants of Public Drug Expenditures
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 8A
________________________________
_____________________
Slide 17
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 8B
________________________________
_____________________
Slide 18
________________________________
________________________________
FIN 8C
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
16
Slide 19
________________________________
Criteria for Evaluation of Funding
Alternatives
Access: Extent to which drugs are available and
affordable
Equity: Effect on fairness or justness of distribution of
goods and services
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 9A
________________________________
_____________________
Slide 20
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 9B
________________________________
_____________________
Slide 21
FIN 9C
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
17
Slide 22
________________________________
Illustrative Comparison of
Funding Mechanisms
FUNDING
MECHANISM
Availability of
Essential
Drugs
(Access)
Public
Financing
Through
Government
Budgets
User Charges
i Government
revolving
drug funds
(RDF)
Appropriate
Drug Use
Efficiency
Sustainability
Administrative
Requirements
________________________________
________________________________
________________________________
i Community
drug
schemes
Equity
________________________________
________________________________
FIN 10A
________________________________
_____________________
Slide 23
________________________________
Illustrative Comparison of
Funding Mechanisms, cont.
Funding
Mechanism
i Direct
private
drug
purchases
Health
Insurance
i Social
i Private
Availability of
Essential
Drugs
(Access)
Appropriate
Drug Use
Efficiency
Equity
Sustainability
Administrative
Requirements
________________________________
n
sector
r
p
________________________________
________________________________
needed
________________________________
i Managed
care
________________________________
FIN 10B
________________________________
_____________________
Slide 24
________________________________
Illustrative Comparison of
Funding Mechanisms, cont.
Funding
Mechanism
Availability of
Essential
Drugs
(Access)
Appropriate
Drug Use
Efficiency
Equity
Sustainability
Administrative
Requirements
________________________________
Community
Financing
Donor
Financing
________________________________
Bilateral
Development
loans
________________________________
yes
________________________________
________________________________
FIN 10C
________________________________
_____________________
18
Slide 25
________________________________
Summary of Session
Complementary approaches are necessary
If essential drug supply is inadequate, the FSE is
unbalanced. Decision makers have four options:
1. improve efficiency
2. control demand
3. increase funds
4. accept a decline in quality
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 11A
________________________________
_____________________
________________________________
Slide 26
Summary of Session, cont.
Efficiency should be improved in the public and private
health sectors
When improved efficiency and demand do not balance
the FSE, there are four options for increased funding:
1. Greater government funding
2. Introducing or strengthening user fees
3. Introducing or expanding health insurance
4. Obtaining donor assistance
________________________________
________________________________
________________________________
________________________________
________________________________
FIN 11B
________________________________
_____________________
Slide 27
________________________________
Summary of Session, cont.
There are no magical solutions to the problems of
health and drug financing
The challenge is to make optimal use of each
available source of financing
________________________________
________________________________
________________________________
________________________________
FIN 11C
________________________________
________________________________
_____________________
19
Slide 28
________________________________
Summary of Session, cont.
________________________________
________________________________
________________________________
________________________________
________________________________
________________________________
_____________________
20